XML 29 R23.htm IDEA: XBRL DOCUMENT

Certain Financial Statement Caption Information (Tables)

6 Months Ended

Jun. 30, 2025

Certain Financial Statement Caption Information [Abstract]

Schedule of Company's Short-Term Investments

The following table summarizes the Company’s short-term investments (in thousands):


		Maturity		Amortized				Unrealized				Unrealized				Estimated
		(in years)		Cost				Gains				Losses				Fair Value
December 31, 2024
U.S. treasury securities		1 or less		$	4,487			$	3			$	-			$	4,490
Total				$	4,487			$	3			$	-			$	4,490

Schedule of Accrued Expenses

Accrued expenses consisted of the following (in thousands):


		June 30,				December 31,
		2025				2024
Accrued payroll and other employee benefits		$	247			$	437
Clinical development			1,753				1,962
Other accruals			129				303
Biocon and its subsidiaries chemistry, manufacturing and controls services - related party			56				43
Biocon clinical development related to ulcerative colitis study - related party			56				223
Non-clinical research			14				150
Income tax accruals			17				365
Total accrued expenses		$	2,272			$	3,483